Cancer is one of society’s most significant challenges, with most cancer being detected too late. Early detection technology could address a tremendous unmet need and reduce the cancer burden worldwide. GRAIL has combined forces with Illumina to enable broader and faster adoption of GRAIL’s innovative, multi-cancer early detection blood test, enhancing patient access and expanding global reach.
https://grail.com/press-releases/illumina-to-acquire-grail-to-launch-new-era-of-cancer-detection/